These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8911706)

  • 1. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro.
    Buscaglia S; Paolieri F; Catrullo A; Fiorino N; Riccio AM; Pesce G; Montagna P; Bagnasco M; Ciprandi G; Canonica GW
    Clin Exp Allergy; 1996 Oct; 26(10):1188-96. PubMed ID: 8911706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
    Ciprandi G; Buscaglia S; Catrullo A; Pesce G; Fiorino N; Montagna P; Bagnasco M; Canonica GW
    Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
    Ciprandi G; Cosentino C; Milanese M; Tosca MA
    Ann Allergy Asthma Immunol; 2003 Apr; 90(4):434-8. PubMed ID: 12722967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
    Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
    J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge.
    Ciprandi G; Buscaglia S; Pesce G; Passalacqua G; Rihoux JP; Bagnasco M; Canonica GW
    J Allergy Clin Immunol; 1995 Feb; 95(2):612-21. PubMed ID: 7531732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiallergic activity of topical lodoxamide on in vivo and in vitro models.
    Ciprandi G; Buscaglia S; Catrullo A; Paolieri F; Riccio AM; Fiorino N; Canonica GW
    Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.
    de Graaf-in 't Veld T; Garrelds IM; van Toorenenbergen AW; Mulder PG; Gerth van Wijk R; Boegheim JP
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):261-6. PubMed ID: 7552929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
    Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
    Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of topical levocabastine compared with oral terfenadine.
    Bahmer FA; Ruprecht KW
    Ann Allergy; 1994 May; 72(5):429-34. PubMed ID: 7909999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge.
    Ciprandi G; Buscaglia S; Pronzato C; Benvenuti C; Cavalli E; Bruzzone F; Canonica GW
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):446-52. PubMed ID: 7583868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine.
    Qasem AR; Bucolo C; Baiula M; Spartà A; Govoni P; Bedini A; Fascì D; Spampinato S
    Biochem Pharmacol; 2008 Sep; 76(6):751-62. PubMed ID: 18680729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis.
    Ciprandi G; Cerqueti PM; Sacca S; Cilli P; Canonica GW
    Ann Allergy; 1990 Aug; 65(2):156-8. PubMed ID: 1974402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal levocabastine provides fast and effective protection from nasal allergen challenge.
    Bachert C; Wagenmann M; Vossen-Holzenkamp S
    Rhinology; 1996 Sep; 34(3):140-3. PubMed ID: 8938880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression.
    Ciprandi G; Pronzato C; Ricca V; Passalacqua G; Danzig M; Canonica GW
    Clin Exp Allergy; 1997 Oct; 27(10):1175-83. PubMed ID: 9383258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetirizine modulates adhesion molecule expression in a double-blind controlled study conducted in psoriatic patients.
    Pestelli E; Floriani I; Fabbri P; Caproni M
    Int J Tissue React; 2003; 25(1):1-8. PubMed ID: 12854881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of HLA-DR antigen and ICAM-1 molecule expression on airway epithelial cells by sodium nedocromil.
    Sacco O; Lantero S; Scarso L; Galietta LJ; Spallarossa D; Silvestri M; Rossi GA
    Ann Allergy Asthma Immunol; 1999 Jul; 83(1):49-54. PubMed ID: 10437816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deflazacort protects against late-phase but not early-phase reactions induced by the allergen-specific conjunctival provocation test.
    Ciprandi G; Buscaglia S; Pesce GP; Iudice A; Bagnasco M; Canonica GW
    Allergy; 1993 Aug; 48(6):421-30. PubMed ID: 7902021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.